BAYER AG NA
Commented by Fabian Lorenz on October 31st, 2026 | 05:38 CET
Bayer and MustGrow Are Making Concrete Progress, While CTS Eventim Is Entering an Interesting Phase
Created and published on behalf of MustGrow Biologics Corp.
Is CTS Eventim facing turbulent times? An activist US investor is applying pressure, which is unlikely to please founder and major shareholder, Klaus-Peter Schulenberg. The entrepreneur is known for his independent-minded approach and reluctance to compromise. The situation could have implications for the company's share price. MustGrow could also be approaching a significant turning point. Analysts see considerable upside potential, and the company is benefiting from its partnership with Bayer. The two companies recently even held a joint webcast. Bayer itself has also reported positive news, including an important regulatory approval in China.
Commented by André Will-Laudien on October 29th, 2026 | 05:39 CET
Life Sciences in Focus as Sector Rotation Takes Shape: Bayer, Vidac Pharma, Eli Lilly, Novo Nordisk and Evotec in 2027
AI is consolidating, and the Life Sciences sector is firing up its first turbo: Rising healthcare spending, the demographic ageing wave and a veritable wave of innovation are catapulting the industry straight into a multi-year supercycle – and now the major players are reallocating their capital. AI and high-tech have delivered their returns, and now the new outperformers for 2027 are stepping into the spotlight. The catch: after years of heavy losses, most stocks are trading close to their 5-year lows. That will not last! Some companies are already waiting in the wings, with the painful restructuring completed. Leading the way, Novo Nordisk continues its relentless advance as the undisputed flagship of the global obesity and diabetes wave. A genuine hidden gem for return hunters is Vidac Pharma. Through its research into the Warburg effect, the biotech firm is revolutionising cancer therapy and, as a classic high-beta play, adds a dash of spice to opportunity-focused portfolios. The giant Bayer is also back, consistently using the current valuation lull as a major entry opportunity to ignite the next phase of growth with a revamped pipeline. The power quartet is completed by Hamburg-based drug discovery company Evotec, which benefits directly from demand for complex therapies as an indispensable infrastructure and development partner. Those who want to stay ahead in the coming Life Sciences boom need to set the course for their portfolio now!
Read
Commented by Carsten Mainitz on October 28th, 2026 | 05:30 CET
Sow First, Reap Later! Exciting Developments at MustGrow, Bayer and K+S – Who Is Best Positioned?
Created and Published on Behalf of MustGrow Biologics Corp.
Fewer chemicals, healthier soils and higher yields. Agriculture is looking for solutions that combine environmental protection and economic viability. Political support appears to be emerging from Brussels. The EU plans to approve biological crop protection products more quickly and reduce the administrative burden. However, the Council and the European Parliament still need to reach an agreement. At least the direction is right, which could open new opportunities for companies like MustGrow. The Canadians develop mustard-based agricultural products and cooperate with Bayer on biological crop protection through a licensing partnership. The first development milestone payment was made under this partnership in the summer. Bayer's agricultural division focuses on seeds and crop protection. K+S supplies potassium- and magnesium-based fertilisers for agriculture. Ultimately, all three companies face similar challenges: new and existing products must improve yields per hectare while remaining economically viable for farmers. Which stock offers the most value for investors?
Read
Commented by André Will-Laudien on October 27th, 2026 | 05:34 CET
Strong Stock Gains from the Green Transition! How Coca-Cola, Bayer, MustGrow and PepsiCo Are Preparing for the Future
Created and Published on Behalf of MustGrow Biologics Corp.
Despite regulatory progress, global food security remains precarious. According to a recent report by Welthungerhilfe and partner organisations, around a tenth of the world's population suffers from acute malnutrition. Global crises such as climate change and armed conflicts are further exacerbating the situation. Large corporations must therefore go beyond statutory minimum standards and guarantee fair purchase prices to strengthen the resilience of smallholder farms. Only by firmly linking corporate due diligence with sustainable farming practices can the UN Sustainable Development Goal of ending hunger be achieved in the long term. To steer multinational corporations' market power toward more sustainable practices, the European Union is increasingly turning to regulation. A key instrument is the EU Corporate Sustainability Due Diligence Directive (CSDDD), which, from 2026, is intended to require comprehensive compliance with human rights and environmental standards throughout the value chain. Large agricultural and food companies must therefore demonstrate that their suppliers do not destroy local livelihoods, such as access to clean drinking water or fertile land. For investors, these developments are creating a range of opportunities around an emerging megatrend. Allocating a portion of a portfolio to the food, beverage and crop science sectors may therefore make sense.
Read
Commented by Armin Schulz on October 27th, 2026 | 05:21 CET
Pharma Stocks with a Future: Bayer, BioNxt Solutions and Novo Nordisk Expand Their Pipelines
No pharmaceutical company can rely on its bestsellers forever. Eventually, patent protection expires, generic manufacturers enter the market, and margins come under pressure. Companies that fail to replenish their product pipelines risk being left behind. That is why substantial sums are currently flowing into new active ingredients, manufacturing facilities and innovative drug delivery methods. Bayer plans to invest USD 2.2 billion in a pharmaceutical plant in Ohio. Smaller developers such as BioNxt Solutions are exploring new formulations and delivery methods for established active ingredients. At the end of September, Novo Nordisk agreed to license an oral drug candidate, including an upfront payment of USD 300 million. We take a closer look at Bayer, BioNxt Solutions and Novo Nordisk.
Read
Commented by Nico Popp on October 20th, 2026 | 10:04 CEST
Time Limit, Not a Free Pass: What the EU’s Pesticide Decision Means for Bayer, BASF and MustGrow Biologics
Created and Published on Behalf of MustGrow Biologics Corp.
On September 30, 2026, the Council of the European Union took a position against indefinite authorisations for synthetic plant protection products and set a maximum term of 15 years for initial authorisations and 25 years for renewals. The member states intend indefinite approvals to be reserved in future for substances with a proven low risk. The member states aim to reach a provisional agreement with the European Parliament by the end of 2026. Regular reassessment of active substances will therefore remain in place for the agrochemical industry, while biological alternatives gain in importance. We analyse the development and present three companies.
Read
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Fabian Lorenz on October 9th, 2026 | 07:30 CEST
Deutz Stock Under Pressure! Buy Recommendations for Bayer and Partner MustGrow Biologics
Created and Published on Behalf of MustGrow Biologics Corp.
What is going on with Deutz? The Cologne-based company had emerged as a favourite among investors looking to capitalize on the defence boom. But after more than doubling in just a few months, the stock has recently fallen by around 20%. There are clear reasons for the pullback—but should investors be worried? There is certainly reason for optimism at MustGrow. The US commercialization of the soil-fertility product TerraSante™ has begun, and demand is outpacing supply. Contract manufacturers now need to ramp up production quickly. Analysts expect revenues and earnings to rise sharply in the coming years. A partnership with Bayer is also expected to contribute to this growth. Bayer, meanwhile, plans to expand its US presence with a multibillion-dollar investment. The stock is not currently benefiting from this development. Nevertheless, analysts are recommending the shares as a Buy.
Read
Commented by André Will-Laudien on October 7th, 2026 | 09:00 CEST
Droughts, Floods, Wars! Crisis-Resilient Returns with Global Food Stocks Like Unilever, MustGrow, Bayer and Kraft Heinz
Created and Published on Behalf of MustGrow Biologics Corp.
In times of heightened geopolitical and climate-related crises, the food and agriculture sector is emerging as an increasingly critical industry. Droughts, storms, and devastating floods are presenting the global food industry with ever-greater challenges. Companies in this sector are committed to ensuring basic food security and are also driving the adoption of more sustainable farming practices. For investors, Bayer, Unilever, MustGrow, and Kraft Heinz are being put to the test, with their fundamental strength facing increasingly difficult conditions. British consumer-goods giant Unilever, for example, is placing greater emphasis on regenerative agriculture while leveraging its portfolio of global brands. US food giant Kraft Heinz, meanwhile, is seeking to withstand inflation and volatile supply chains with its portfolio of established consumer brands. At the same time, biotech company MustGrow is positioning itself with sustainable agricultural solutions designed to address increasingly extreme weather conditions, while collaborating with crop-science specialist Bayer. Current challenges are pushing food producers' business models to their limits. A closer look at the key metrics reveals who is truly prepared for the future of food.
Read